{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-071822","form_type":"8-K","ticker":"CLRB","cik":"0001279704","company_name":"Cellectar Biosciences, Inc.","filed_at":"2024-06-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.693275+00:00","generated_at":"2026-06-01T04:15:24.110815+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Cellectar stockholders approve increase in share reserve by 7M shares, re-elect directors","bullets":["Stockholders approved amendment to 2021 Stock Incentive Plan, increasing shares reserved by 7,000,000 (14.5M for, 1.06M against).","Class I directors Asher Chanan-Khan and John Neis re-elected with 15.4M and 14.9M votes for, respectively.","Ratification of Baker Tilly US, LLP as independent auditor for FY2024 approved (25.8M for, 183k against).","Non-binding advisory vote on executive compensation approved (15.1M for, 436k against).","No departures or other material changes reported."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-071822","json":"https://secwatch.observer/filing/0001104659-24-071822.json","markdown":"https://secwatch.observer/filing/0001104659-24-071822.md","text":"https://secwatch.observer/filing/0001104659-24-071822.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1279704/000110465924071822/0001104659-24-071822-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1279704/000110465924071822/tm2417372d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T04:15:24.110815+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}